Dallas, TX – June 8, 2021 – Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announced today it is preparing to launch a marketing and sales campaign of its recently enhanced sublingual spray line (which is applied via a spray into the mouth).
These sublingual sprays are made using RTSL’s proprietary pharmaceutical grade isolates in blends for multiple flavors and terpenes. In addition, the sprays are manufactured on the same exact equipment as RTSL’s metered dose inhalers (MDI), in the company’s existing ISO Level 6 laboratory, following Good Manufacturing Practice (GMP) standards.
RTSL’s CEO, Donal R. Schmidt, Jr. stated, “Our decision to file an IND application for our flagship MDI containing Cannabidiol (CBD), as previously announced, requires we remove this MDI product from the market while the application is pending. Nevertheless, this removal will not affect our use of pure pharmaceutical isolates formulas we have developed or our existing aerosol equipment. In fact, in addition to the sublingual sprays we are preparing to market, we are also testing nasal sprays and topical sprays, using our existing equipment and formulas for planned delivery in the fourth quarter.”
These products are expected to be sold both as branded products and on a white label basis in RTSL’s existing sales channels.
Mr. Schmidt continued, “Based upon discussions with our existing customers, as well as new contacts, we expect significant demand for these products. Although the bioavailability of a sublingual spray is generally not as high as an MDI, it nonetheless typically has higher bioavailability than oral pills and topicals. Regardless, when we discussed the availability of the sublingual spray products with our customers, almost all of them recognize that our specifically manufactured pharmaceutical grade isolates set us apart from other hemp product producers. In short, we have a non-toxic, pure isolate product that deliverers the exact dose each and every use.”
In conclusion, Mr. Schmidt observed that, “RTSL is branding itself as a biopharmaceutical outlier in the hemp space. We make pure products with pharmaceutical grade components on well proven aerosol equipment that delivers safe non-toxic products at known consistent dosage.”
About Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL)
RTSL has developed a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more cannabinoid compounds. The Company’s nhāler product line is manufactured in compliance with GMP.
CBD is not approved by the FDA.
We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our other products. Always consult a physician prior to using any cannabinoid product. RTSL makes no therapeutic claims regarding its products, the use of its products, or any results which can be obtained from using its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. If you experience any adverse reaction of any non-psychotropic cannabinoid, stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act). Our products contain zero THC.
Visit our corporate website at www.rtslco.com.
This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov.
Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements which include, among others, the planned timing of product availability, the demand for such products, and our ability to produce significant quantities of such products.
The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
SOURCE: Rapid Therapeutic Science Laboratories, Inc.